Grok AI Market Share Surges as xAI Faces Scrutiny Over Image Generation Controversy 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
Lockheed Martin Secures $101M in U.S. Defense Contracts for AEGIS, F-35, and Missile Systems 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
AUSTIN, Texas, Nov. 03, 2017 -- XBiotech Inc. (NASDAQ:XBIT) announced today that research involving MABp1, the company’s IL-1 alpha (IL-1α) antibody, will be featured in an oral presentation during the American Heart Association Scientific Sessions being held November 11-15 in Anaheim, California. The presentation will provide evidence that IL-1α is associated with Neutrophil Extracellular Traps (NETs) and is involved in endothelial activation and thrombogenesis.
| Title: | Neutrophil Extracellular Traps Increase Endothelial Activation and Thrombogenicity via IL-1α and NF-κB: Implications for Superficial Erosion | |
| Session: | Endothelial Dysfunction in Vascular Disease | |
| Date: | Monday, November 13, 2017 | |
| Time: | 5:45 p.m. – 5:55 p.m. (Pacific Time) | |
| Location: | Anaheim Convention Center, Anaheim, CA | |
About True Human™ Therapeutic Antibodies
XBiotech’s True Human™ antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech’s True Human antibodies have the potential to harness the body’s natural immunity to fight disease with increased safety, efficacy and tolerability.
About XBiotech
XBiotech is a fully integrated global biosciences company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies based on its True Human™ proprietary technology. XBiotech currently is advancing a robust pipeline of antibody therapies to redefine the standards of care in oncology, inflammatory conditions and infectious diseases. Headquartered in Austin, Texas, XBiotech also is leading the development of innovative biotech manufacturing technologies designed to more rapidly, cost-effectively and flexibly produce new therapies urgently needed by patients worldwide. For more information, visit www.xbiotech.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including declarations regarding management's beliefs and expectations that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "would," "could," "expects," "plans," "contemplate," "anticipates," "believes," "estimates," "predicts," "projects," "intend" or "continue" or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the "Risk Factors" section of certain of our SEC filings. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
Contact
Ashley Otero
[email protected]
512-386-2930
